Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program.

Plain-language guide to PMID 33709288 (2021): multicenter observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 33709288
Journal: Pituitary
Year: 2021
Study type: Observational Study
Authors: Biller BMK et al. (8 authors)
DOI: 10.1007/s11102-021-01138-3
Registered trial: NCT00960128, NCT01009905

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as an observational study.

Data on the safety of growth hormone (GH) replacement therapy during pregnancy are limited.

The researchers report a combined analysis of data from pregnant women treated with GH while enrolled in two non-interventional, multicenter studies: NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) Program.

Why It Was Studied

ClinicalTrials.gov NCT00960128 (date of registration: August 13, 2009) and NCT01009905 (date of registration: November 5, 2009).

Who Took Part

PubMed tags the participants as women only.

Patients exposed to GH replacement therapy during pregnancy were included in the analysis.

How the Study Was Run

The design is described as multicenter.

More than one site took part, so the participants came from several places.

Pregnancy data were pooled from NordiNet® IOS and the ANSWER Program.

Data were collected during routine clinic visits by participating physicians using a web-based system.

What Was Measured

PubMed files the paper under topics including Dwarfism, Pituitary, Growth Hormone, Hormone Replacement Therapy, Human Growth Hormone, Insulin-Like Growth Factor I, Outcome Assessment, Health Care and Pregnancy Outcome.

Author keywords: Adult growth hormone deficiency and IGF-I.

What This Means in Plain Language

The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The abstract goes on to report its results in about 11 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Pituitary), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.